End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link?
about
Oxidative Stress in Diabetic Nephropathy with Early Chronic Kidney DiseaseCardiac troponin and C-reactive protein for predicting all-cause and cardiovascular mortality in patients with chronic kidney disease: a meta-analysis.Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study.The severe cardiorenal syndrome: 'Guyton revisited'.Why do young people with chronic kidney disease die early?Metabolic syndrome, chronic kidney disease, and cardiovascular disease: a dynamic and life-threatening triad.Association between periodontitis and mortality in stages 3-5 chronic kidney disease: NHANES III and linked mortality study.Vascular access type, inflammatory markers, and mortality in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) StudyDissecting the mechanisms of left ventricular diastolic dysfunction and inflammation in peritoneal dialysis patients.Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysisRosuvastatin in diabetic hemodialysis patientsC-reactive protein and cardiovascular disease: new insights from an old molecule.Influence of ACE I/D Polymorphism on Circulating Levels of Plasminogen Activator Inhibitor 1, D-Dimer, Ultrasensitive C-Reactive Protein and Transforming Growth Factor β1 in Patients Undergoing HemodialysisVision-threatening retinal abnormalities in chronic kidney disease stages 3 to 5.Low-grade inflammation, metabolic syndrome and the risk of chronic kidney disease: the 2005 Korean National Health and Nutrition Examination Survey.The Growth Attainment, Hematological, Iron Status and Inflammatory Profile of Guatemalan Juvenile End-Stage Renal Disease PatientsNT-proBNP: is it a more significant risk factor for mortality than troponin T in incident hemodialysis patients?Subnormal Estimated Glomerular Filtration Rate Strongly Predict Incident Cardiovascular Events in Type 2 Diabetic Chinese Population With Normoalbuminuria.Effects of zinc supplementation on plasma copper/zinc ratios, oxidative stress, and immunological status in hemodialysis patients.Impact of uremia on human adipose tissue phenotype.Is it time to revisit residual renal function in haemodialysis?Inflammatory factors and exercise in chronic kidney disease.Appropriateness of carotid plaque and intima-media thickness assessment in routine clinical practice.Which Biomarker is the Best for Predicting Mortality in Incident Peritoneal Dialysis Patients: NT-ProBNP, Cardiac TnT, or hsCRP?: A Prospective Observational StudyDynamic changes of carotid artery intima-media thickness and mortality in hemodialysis patients.C-reactive protein and other markers of inflammation in hemodialysis patients.Serum C-reactive protein levels in pre-dialysis chronic kidney disease patientsin southern Nigeria.Association of chronic kidney disease with periprocedural myocardial injury after elective stent implantation: A single center prospective cohort study.Concomitant impact of high-sensitivity C-reactive protein and renal dysfunction in patients with acute myocardial infarctionContinuous ambulatory peritoneal dialysis patients show high prevalence of carotid artery calcification which is associated with a higher left ventricular mass index.Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in hemodialysis patients.The importance of residual renal function in chronic dialysed patients.Statins, inflammation and kidney disease.The effect of statin therapy on the formation of arteriovenous fistula stenoses and the rate of reoccurrence of previously treated stenoses.Water quality in conventional and home haemodialysis.Pathogenesis of chronic cardiorenal syndrome: is there a role for oxidative stress?Statins in chronic kidney disease: cardiovascular risk and kidney function.Clinical Outcomes in Dialysis Patients: Prospects for Improvement with Aldosterone Receptor Antagonists.Interaction of Soluble CXC Ligand 16 and Cardiac Injury Markers in Hemodialysis Patients.The inflammation-lipocalin 2 axis may contribute to the development of chronic kidney disease.
P2860
Q26741451-B96D3380-A0E4-4311-92FB-0A91BF960F88Q27687888-E16DEA21-4808-42A4-AFAF-0549AB7CAF30Q34023357-AD6682E5-CBF0-47F9-963B-348F071F7FBBQ34379161-DD71F5A3-5331-4EB6-B7AE-554DC4664519Q34453230-5D3A9B26-1378-4B5A-8D7E-21C728C10230Q34595173-144BECEA-5BB0-4F4F-B03C-614ADF3EADF5Q34675029-583699A0-3B42-4D47-B559-27471452A435Q34693036-91F01EC9-173F-4B34-947F-53C4D1DF5C1BQ34722642-65049294-37A7-49EB-B14B-CA64C9D3C3F1Q35030586-21A5690E-C76A-4658-B858-49B00EF15095Q35108893-89BDCF7B-79E9-40F9-9264-9A41E1445A6AQ35562701-C735E061-B886-4EA6-B9A1-FCB222462145Q35972437-68C877A2-3E6F-45FA-A818-679D9239CD92Q35985754-07E08858-9CE2-4877-BDFA-2762F7A8E1C5Q36014454-D2B79DE9-669D-4E1B-A75C-64A1CF40E72EQ36133152-A484CF02-67A8-423F-A1D9-4400C1B227A7Q36152500-6A81CD5A-7B9B-43E8-B22B-B3232E50B2CDQ36478002-9073D029-F046-40D7-8DBA-0C667EB3AD05Q36501530-E7A10DA5-8895-44DF-A984-9B1E3D37E37CQ36637146-A663DACA-61C5-4753-A8DF-CF684703B877Q36820013-A1A23FFF-C129-46BC-A391-FBD2BAF9ACB6Q36882794-B1798568-306F-4A78-93C8-38C4B3B941D0Q36956790-19864599-1051-46EE-833E-0B6A28DF7C98Q37026079-72483C96-9EB6-4169-8C88-7717906DAC33Q37078465-F7ED3775-D22F-4771-8354-A13F3398F667Q37145257-817FE481-9D93-4A21-B30E-E07858C33FCDQ37196568-A4121254-B7AA-463F-80F5-1E785A05BBC0Q37409610-9515B5E2-BBF5-406A-BF49-384D1283F8CDQ37418872-CA368569-EC0C-4D18-A54E-C32340692272Q37425715-514E6EFC-E11D-43F9-A752-0DB2D224868AQ37449096-40E12C6D-39AF-4AB6-8C59-59711089014DQ37682811-35BA40BF-109E-419F-B19E-58ACFE6B5A1AQ37883015-62AE511B-0456-47DB-AEC4-BD9B5F04A262Q38053178-11AA21DF-019C-4427-BBA4-25A24404B43EQ38054515-F37DFA39-1A3B-421D-97AB-54B02FD553E3Q38165049-661B0CFB-B293-43A8-BCBD-2B4AEC6C67AEQ38176142-0C5C56C7-2631-4DE1-B54E-0779EBF2E719Q38560705-44098BC1-0FB0-4716-B41C-8D853B8A66F5Q38717039-78768BDD-2867-43CE-A034-F43B8AD41BCAQ39062964-E21E7B96-5638-4686-84B5-C98BE1AF1FD7
P2860
End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link?
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
End-stage renal disease, ather ...... tive protein the missing link?
@ast
End-stage renal disease, ather ...... tive protein the missing link?
@en
End-stage renal disease, ather ...... tive protein the missing link?
@nl
type
label
End-stage renal disease, ather ...... tive protein the missing link?
@ast
End-stage renal disease, ather ...... tive protein the missing link?
@en
End-stage renal disease, ather ...... tive protein the missing link?
@nl
prefLabel
End-stage renal disease, ather ...... tive protein the missing link?
@ast
End-stage renal disease, ather ...... tive protein the missing link?
@en
End-stage renal disease, ather ...... tive protein the missing link?
@nl
P1433
P1476
End-stage renal disease, ather ...... tive protein the missing link?
@en
P304
P356
10.1046/J.1523-1755.2001.059002407.X
P407
P577
2001-02-01T00:00:00Z
P5875
P6179
1000125591